What is Median Technologies?
Median Technologies is a technology company specializing in medical imaging and image analysis solutions for clinical trials. Founded in 2002, the company has quickly established itself as a global leader in its field, offering innovative solutions for the interpretation and analysis of medical images.
Median Technologies products and services
Median Technologies offers a full range of products and services for medical image analysis, including:
– iBiopsy®:
an artificial intelligence platform that enables automated analysis of medical images, providing precise and detailed information about tissues and lesions. This revolutionary technology allows researchers and clinicians to obtain more reliable data more quickly to make informed decisions.
Image analysis software:
Median Technologies also offers specific software for medical image analysis, such as LesionQuant™ and LMS, which enable accurate assessment of lesions and more effective monitoring of disease progression.
Median Technologies on the stock market
Median Technologies, listed under the symbol ALMDT on Euronext Paris, is active in the software sector. At the recent close of writing this article, the stock was trading at 3.860 euros, recording an increase of 1.98% compared to the previous session. The trading day saw the stock move between 3,720 euros and 3,860 euros, with a volume of 26,808 shares traded.
The market capitalization of the company stands at 71 million euros, with a percentage of capital traded of 0.15% in the last trading session. It should also be noted that the action is eligible for PEA and PEA-PME, indicating a certain flexibility for French individual investors in terms of tax advantages.
The company has also managed to diversify its activities by developing partnerships with clinics and hospitals for the use of its image analysis technologies in medical diagnostics and treatments. These partnerships also allow Median Technologies to develop and market its products and services within the framework of large-scale clinical trials.
Financial and operational performance of Median Technologies in 2023
- 2023 turnover: 22.2 million euros, a figure down compared to the previous year, mainly due to low order intake in China, affected by the confinements linked to Covid in 2022 and the first half of 2023.
- Backlog: Reached a record level of €66.9 million at the end of the year, illustrating strong demand for its clinical imaging services (iCRO) and confirming the growing interest in artificial intelligence in trials oncology clinics.
- Funding: The company has secured its financial position until the second quarter of 2025, thanks to a successful refinancing in July 2023 and a drawing of 8.5 million euros at the beginning of 2024, as part of a loan granted by the Bank European Investment Corporation (EIB).
Innovations and Technological Advances
- eyonis™ LCS (Lung Cancer Screening): Median has completed pivotal studies for eyonis™ LCS, a Software as a Medical Device (SaMD), with results from an independent verification study showing exceptional performance. They aim to achieve FDA 510(k) clearance and CE marking by 2025, with significant market potential in the United States and Europe for early detection of lung cancer.
- Detection of Hepatocellular Carcinoma (HCC): The AI eyonis™ HCC model showed promising results, with a sensitivity rate of 92% for detecting HCC lesions as small as 10 mm in diameter, surpassing average detection rates without AI assistance.
The evolution of Median Technologies shares on the stock market
The evolution of Median Technologies shares on the stock market has been remarkable over the last few years. Since its IPO, the stock has experienced sustained growth, reflecting investor confidence in the company’s growth prospects.
Due to the company’s increasing expansion in the global market and its leading position in the field of medical imaging, many financial analysts believe that Median Technologies stock has strong long-term growth potential. .
Median Technologies’ outlook for 2024
Median Technologies outlined several key objectives for 2024, including the expansion of its iCRO activities, the development of strategic partnerships in pharmaceuticals and global diagnostics, as well as the advancement of its clinical studies for eyonis™ LCS.
This information highlights Median Technologies’ position as an innovative player in the field of medical imaging and artificial intelligence, despite the challenges faced in 2023. Their strategic approach and development pipeline promise continued growth and expansion in the years to come
